

2015

		3
		4
		5
		6
	(+)	6
		6
		6
		7
		7
	+	9
,	<i>Str.Pneumoniae</i>	11
		12
		12
		13
		13
		14
		15
		16
		17
		18
		20

ADAMTS 13 –

,

C3 – 3

CFB – B

CFH – H

CFI – I

HELLP- –

,

HLA –

KDIGO -

[Kidney Disease: Improving Global Outcomes (KDIGO)]

STEC – - E.Coli

THBD –

- -

- -

+ - - ,

-

-

- -

-

-

-

-

-

-

-

-

-

XVIII

2015 .

» 14

... :

... / ... :

-5 ... EMBASE, MEDLINE PubMed. ... ;

... ; ...

(Good Practice Points – GPPs)

-
-

(-)

().

(1-2)

(-
 . 1) – good practice points (GPPs)

1.

1			

<p>1</p> <p>,</p>	<p>,</p>	<p>(</p> <p>,</p> <p>,</p> <p>),</p> <p>(</p> <p>,</p>	<p>,</p>
<p>1</p> <p>,</p>	<p>,</p> <p>,</p>	<p>,</p> <p>,</p> <p>,</p> <p>.</p>	<p>,</p>
<p>2</p> <p>,</p>		<p>,</p> <p>.</p>	<p>.</p> <p>(</p> <p>),</p> <p>.</p>
<p>2</p> <p>,</p>	<p>,</p> <p>.</p>	<p>(</p> <p>,</p> <p>,</p> <p>),</p> <p>-</p> <p>(</p> <p>),</p> <p>.</p>	<p>.</p>
<p>2</p> <p>,</p>	<p>,</p> <p>;</p> <p>.</p>	<p>,</p> <p>.</p> <p>.</p>	<p>;</p> <p>.</p>

(.2), , 1, 2 « »
 , , (.3).

1.

(KDIGO)

1 - « »	,	,	
2 - « »	,	,	,
« ()	,	-	,

2.

(KDIGO)

-	,
-	,
-	
D -	

1.

1.1 6 3

1.2

1.3

(, ,)

-

1.4

-

E.Coli,

IgM-

.(1A)

1.5

,
,

()

.(1B)

1.6

.(2B)

1.7

.(1A)

1.8

,
.(2B)

1.9

,

2

2.1

-

,

,

,

,

-

-

,

2.2

ADAMTS 13

.(1A)

2.3

- ,
.(1B)

2.4

(CFH) - .(1B)

2.5

- 5 ,
.(1B)

2.6

.(2B)

2.7

.(2B)

2.8

-
: CFH, CFI, CFB, C3, THBD, MCP. (2B)

_____ - ()
 () . :

- (), ().
 () -

,
 , [23, 24].

(90-95%) -
 , (+) *Escherichia coli*,
 . . (Shigatoxine; Stx) (Stx- *E coli*, STEC).

, (), (5-10 %
) () ,
 [6, 13, 20].

-10

D59.3 -

_____ (- , STEC-) -
 _____: + , STEC ,
 2-3 10000 3 [2, 23].
 STEC- 85 % +
 Mac Conkey .
 0157:H7 (O111, O103, O121).
 STEC
 , , , IgM
 [2, 20].
 , , , , , , ,
 , , , , , ,
 . + , ,
 , STEC .
 STEC
 10-20 %
 STEC .
 ,
 (, Gb3) ,
 Gb3, ,
 ,

,
 .
 .
 + (90–95%), (30-60%)
 . 70% 1-2
 6 (2-14) . , , , ,
 , ,
 « » [2, 23].
 :
 - :
 <80 / , (2-10%), 70%
 .
 - (50 000 – 70 000 × 10⁹ /)
 ,
 ,
 - 20 000 × 10⁹/
 .
 -
 , 50-60% . -
 - .
 ,
 ,
 - ,
 - , , , ,
 .
 - :
 - (),
 , 20 % .
 , , , ,
 , , , ,
 .
 , .

[4].

- 10% ;
 , , , ;
 , , .

- 10 % .

- 40% ,

- - ((2%) , , .

-
1. - , , :
 2. - , , (), , , ,
 - 3.
 4. 3 4
 5. / STEC-

+

STEC-

, , .

[2, 20].

_____ -

, ,
, ,
, ,
(2-5 /)
, ,
, ,
, ,
.

_____ : , , ,
100 %

_____ : 70 / .
-HLA
().
()
,)

_____ : (Tenchkoff)

, :
/ ,
.

10 %
 , 25%
 70 - 80 / /1,73 ²,
 :
 5 , 10 ,
 > 20 000 × 10⁹/ , [4].
 20 - 30 [2, 21].

Shigella dysenteriae 1

Shigella dysenteriae 1, ,
 , . ,
 STEC- . 20% ,
 . 20 - 40%. 40 %
 ,
 (3)
 , *Shigella dysenteriae* 1 [2].

Streptococcus pneumoniae

Streptococcus pneumoniae (/) [5],
 2 [1, 9].

Streptococcus pneumoniae N- ,
 () Thomsen-Friedenreich (T-) -
 , , .
 - ,
 , .
 - .
 , 10 %. 10%
 , 20% - ,
 (5).

- IgM ,
 ()

(,),

STEC-

17, 19].

5-10%

(B12) () [13].

1 7 1 . .

(1).
C3bBb, C3 C3b.
C3b (),

(C5b9),

- : H (CFH), I (CFI)
CD46 MCP (, ,

C3b). 3, ,

, ,

[2, 5, 15, 19].

a CFH 20-25 % , MCP 15 % CFI 10 %.
 (CFB) (1 %), C3
 10% .
 (THBD). 10% , 10%
 CFH -CFH .
 30 % a
 [6, 7].

(, ,)
 2/3 . 1/3 ,
 + () [2, 16].

(, ,)
 25% .
 .
 .

() ,
 CFH CFI (6 . 2 . -)
 , MCP 1 .
 . -CFH
 .
 STEC-

»,
« »,
STEC-
(.).

- + ().
STEC- , *Streptococcus pneumoniae*. [3, 12, 16]
H1N1, , HELLP-
(),
(1).

(). ADAMTS 13,
(ADAMTS 13 < 5 %)
ADAMTS 13.
anti-ADAMTS 13 ,

H ,
[11, 16].
CFB , CFH, CFI, C3

[3, 16].

CFH, CFI, C3 CFB,

CFH, CFI, C3, CFB -CFH

[2, 10, 16].

CFH.

MCP

50-60

10-20

5-

5,

5

5b-9

189

[3, 5, 12, 15, 16].

2.

2.

40	900 1 x 4	1200 5- 2 ; 1200
30 - <40	600 1 x 2	900 3- 2 ; 900
20 - <30	600 1 x 2	600 3- 2 ; 600
10 - <20	600 1 x 1	300 2- 2 ; 300
5 - <10	300 1 x 1	300 2- 3 ; 300

/

(7-14)

88%

32 / /1,73²

(64 / /1,73²).

2 .

[15, 16, 27].

(25% 63%

).

10

CFH,

0,5 /1,73²,

CFH.

a

CFH (~ 80 %), CFI

3 (> 50 %).

3

CFB,

MCP ,

1 .

13

24

[7, 14, 25].

CFH, CFI, CFB C3

[22, 25].

5-10 %.

50 %

1

)

20%

MCP.

[18].

MCP

- *CFH*

1

60%

CFH, 37%

CFI, 33%

3, 60%

, 32%

0%

MCP (7).

-*CFH*

[10, 16, 18].

(, , .). , ,
 , ,
 .
 /
 1 - .
 (, ,
) .

-

STEC-

STEC- ()

1. . . . () , 2013 ; 15(2): 116-119
2. . . . : , 2010.-400 .
3. . . . - : , 2010.-400 .
4. . . . 18 2014 , . , 2014 ; 16(2): 304-306
4. . . . (STEC-) : () , 2014 ; 16(3): 328-338
5. Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. *Am J Kidney Dis.* 2012;59:707–10.
6. Ariceta G, Besbas N, Johnson S, Karpman D et al.. Guideline for the investigation and initial therapy of diarrhea-negative haemolytic uremic syndrome. *Pediatr Nephrol* 2009 ; 24 : 687-696.
7. Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. *Clin J Am Soc Nephrol.* 2006;1:88–99
8. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. *Blood.* 2006;108:1267–79.
9. Copelovitch L, Kaplan BS. Streptococcus pneumoniae-associated haemolytic uremic syndrome. *Pediatr Nephrol* 2008 ; 23 : 1951-6.
10. Davin JC, Strain L, Goodship TH. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. *Pediatr Nephrol.* 2008;23:1517–21.
11. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. *J Am Soc Nephrol.* 2005;16:555–63.
12. Fakhouri F, Frémeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: From the rediscovery of complement to targeted therapy. *Eur J Intern Med.* 2013;24:492–5.
13. Geraghty MT, Perlman EJ, Martin LS, Hayflick SJ, Casella JF, Rosenblatt DS, Valle D. Cobalamin C defect associated with hemolytic-uremic syndrome. *J Pediatr.* 1992;120:934–7
14. Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Frémeaux-Bacchi V, Niaudet P. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. *Am J Transplant.* 2012;12:1938–44.
15. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J,

- Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med*. 2013;368:2169–81.
16. Loirat C, Fakhouri F, Ariceta G, Besbas N et al. An international consensus approach to the management of atypical haemolytic uremic syndrome in children. *Pediatr Nephrol* 2015; Published online: 11 April 2015.
 17. Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. *Pediatr Nephrol* 2008 ; 23 : 1957-72.
 18. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clin J Am Soc Nephrol*. 2010;5:1844–59
 19. Noris M, Remuzzi G. Atypical-hemolytic uremic syndrome. *N Engl J Med*. 2009;361:1676–87.
 20. Noris M, Remuzzi G. Hemolytic uremic syndrome. *J Am Soc Nephrol*. 2005;16:1035–50
 21. Oakes RS, Kirkham JK, Nelson RD, Siegler RL. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal haemolytic uremic syndrome. *Pediatr Nephrol* 2008 ; 23 : 1303-8.
 22. Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, Remuzzi G, Strain L, Goodship TH. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. *Am J Transplant*. 2006;6:1948–52.
 23. Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated haemolytic uremic syndrome (HUS). *Pediatr Nephrol* 2008 ; 23 : 1749-60.
 24. Taylor M. Enterohaemorrhagic *Escherichia coli* and *Shigella dysenteriae* type 1-induced haemolytic uraemic syndrome. *Pediatr Nephrol* 2008 ; 23 : 1425-31.
 25. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. *Pediatr Nephrol*. 2011;26:1325–9.
 26. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. for the French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. *Nat Rev Nephrol*. 2012;8:643–657

.1.

	<i>S.pneumonia-</i>		STEC-		
	<2	<2-15% 2-9 – 20% 9-16- 60%	<0,5 – 5% 0,5-3 – 65% >3 – 30%	<0,1 – 50% 1,5-14 – 40% >20 – 10%	0-0,5 – 28% 0,5-2 – 128% 2-15 – 44%
, %			95%, >60%		39%
, %	. - 90%,	$10^9/ < 30 \times$	$30 \times 10^9/ >$		$> 30 \times$ $10^9/ , 15% > 150 \times$ $10^9/$ $>100 \setminus$ 6%
, %	100% 40-80%	,	95% 50%	,	85% 60%
, %	30%	70%	20%	100%	16%
, %			2-5%	55%	2%
		-		-	27%. -
	,	,	,	,	(,)

.1.

Проксимальный
Терминальный

